A Membership required to view content. issued Friday by the Congressional Research Service (CRS) provides a broad overview of the development of the hemp industry, specifically floral hemp and its associated extracts like CBD.
The report highlights the role of the FDA in the emerging hemp industry, and its failure to create a regulatory pathway for CBD. It noted that after years of review by a high-level internal working group, the FDA announced in January it would work with Congress to create a new regulatory pathway for CBD.
…
Membership is required to view the rest of this post.
Click here to learn more and sign up for a free 7-day trial!